Validated Recombinant Proteins for ACE2 & COVID-19 Research
| Product Name | PID | Source | Purity | Application/Activity |
| ACE2 (human) (rec.) | AG-40B-0192 | HEK293 cells | ≥95% (SDS-PAGE) | Soluble human ACE2 competitively inhibits SARS-CoV-2 infection. |
| ACE2 (human) (rec.) (Biotin) | AG-40B-0192B | HEK293 cells | ≥95% (SDS-PAGE) | Soluble human ACE2 competitively inhibits SARS-CoV-2 infection. |
| ACE2 (human) (rec.) (His) | CHI-B232008 | HEK293 cells | ≥90% (SDS-PAGE) | Soluble human ACE2 competitively inhibits SARS-CoV-2 infection. |
| ACE2 (human):Fc (human) (rec.) | CHI-B232006 | HEK293 cells | ≥90% (SDS-PAGE) | Soluble human ACE2 competitively inhibits SARS-CoV-2 infection. |
| ACE2 (mouse) (rec.) | AG-40B-0193 | HEK293 cells | ≥95% (SDS-PAGE) | Soluble mouse ACE2 negative control. |
| SARS-CoV-2 Spike Protein (D614G) (Stable Trimer) (rec.) (His) | AG-40B-6003 | HEK 293 cells | ≥90% (SDS-PAGE) | Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For structural biology research, drug and antibody screening applications and vaccine development. |
| SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) | AG-40B-0195 | HEK 293 cells | ≥95% (SDS-PAGE) | Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (Biotin) | AG-40B-0195B | HEK 293 cells | ≥95% (SDS-PAGE) | This protein forms a tetramer in the presence of streptavidin and this tetramer can be used to activate B cell memory to SARS-CoV-2 Spike protein. |
| SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) | CHI-B232004 | HEK 293 cells | ≥90% (SDS-PAGE) | Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (B.1.1.7 Variant, Alpha) | AG-40B-0205 | HEK 293 cells | ≥95% (SDS-PAGE) | Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (B.1.351 Variant, Beta) | AG-40B-0206 | HEK 293 cells | ≥95% (SDS-PAGE) | Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (P.1 Variant, Gamma) | AG-40B-0207 | HEK 293 cells | ≥95% (SDS-PAGE) | Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (His) (B.1.617.1 Variant, Kappa) | AG-40B-0208 | HEK 293 cells | ≥95% (SDS-PAGE) | Binds to anti-SARS-CoV-2 Spike (RBD) antibodies in serum or plasma. For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD) (rec.) (GST-His) | CHI-B249001 | HEK 293 cells | ≥95% (SDS-PAGE) | Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) | CHI-B232003 | HEK 293 cells | ≥95% (SDS-PAGE) | Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) | AG-40B-0194 | HEK 293 cells | ≥95% (SDS-PAGE) | Soluble Protein S (RBD) competitively inhibits SARS-CoV-2 infection. For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.1.7 Variant, Alpha) | AG-40B-0202 | HEK 293 cells | ≥95% (SDS-PAGE) | More transmissible variant of SARS-CoV-2, called B.1.1.7 that carries a mutation in the RBD at the position 501 (N501Y).For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.351 Variant, Beta) | AG-40B-0203 | HEK 293 cells | ≥95% (SDS-PAGE) | New variant of SARS-CoV-2, called B.1.351, that carries three mutations in the RBD at the positions 417, 484 and 501 (K417N, E484K, N501Y) and is associated with a higher viral load with potential for increased transmissibility. For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (P.1 Variant, Gamma) | AG-40B-0204 | HEK 293 cells | ≥95% (SDS-PAGE) | New variant of SARS-CoV-2, called P.1 that carries three mutations in the RBD at the positions 417, 484 and 501 (K417T, E484K, N501Y). For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.617.1 Variant, Kappa) | AG-40B-0209 | HEK 293 cells | ≥95% (SDS-PAGE) | New variant of SARS-CoV-2, called B.1.617.1 that carries two mutations in the RBD at the positions 452 and 484 (L452R, E484Q). For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.617.2 Variant, Delta) | AG-40B-0211 | HEK 293 cells | ≥95% (SDS-PAGE) | New variant of SARS-CoV-2, called B.1.617.2 that carries two mutations in the RBD at the positions 452 and 478 (L452R, T478K). For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Spike Protein S1 (RBD):Fc (human) (rec.) (B.1.617.2.1 Variant, Delta Plus) | AG-40B-0212 | HEK 293 cells | ≥95% (SDS-PAGE) | New variant of SARS-CoV-2, called B.1.617.2.1 that carries three mutations in the RBD at the positions 417, 452 and 478 (K417N, L452R, T478K). For drug and antibody screening applications and immunization. |
| SARS-CoV-2 Nucleocapsid Protein (rec.) (His) | CHI-B233501 | E. coli | ≥95% (SDS-PAGE) | For drug screening applications. |
| PLpro (SARS Coronavirus) (rec.) (His) | SBB-DE0024 | E. coli | ≥95% (SDS-PAGE) | Involved in the processing of the viral polyprotein. |
| ISG15 (human) (rec.) (Rhodamine 110) | SBB-PS0002 | E. coli | ≥97% (LCMS) | PLPro substrate. Inhibits viral budding and acts as IFNγ-inducing cytokine. |
Originally posted on adipogen.com/covid-19
Caltag Medsystems is the distributor of Adipogen products in the UK and Ireland. If you have any questions about these products, please contact us.
Validated Recombinant Proteins for ACE2 & COVID-19 Research